×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AMGN – amgen inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AMGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/8
09:09 am
amgn
Amgen (AMGN) had its "neutral" rating reaffirmed by Cantor Fitzgerald. They now have a $350.00 price target on the stock.
Low
Report
Amgen (AMGN) had its "neutral" rating reaffirmed by Cantor Fitzgerald. They now have a $350.00 price target on the stock.
4/7
09:42 am
amgn
Amgen (AMGN) had its price target raised by Royal Bank Of Canada from $360.00 to $370.00. They now have an "outperform" rating on the stock.
Low
Report
Amgen (AMGN) had its price target raised by Royal Bank Of Canada from $360.00 to $370.00. They now have an "outperform" rating on the stock.
4/6
09:21 am
amgn
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE [Yahoo! Finance]
Low
Report
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE [Yahoo! Finance]
4/6
09:12 am
amgn
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE [TheStreet.com]
Low
Report
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE [TheStreet.com]
4/6
09:00 am
amgn
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
Low
Report
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
4/2
11:49 am
amgn
Is Amgen Inc. (AMGN) One of the Best Pharma Stocks to Invest in Now? [Yahoo! Finance]
Low
Report
Is Amgen Inc. (AMGN) One of the Best Pharma Stocks to Invest in Now? [Yahoo! Finance]
4/1
10:43 am
amgn
Zai Lab gains after clinical trial pact with Amgen [Seeking Alpha]
Low
Report
Zai Lab gains after clinical trial pact with Amgen [Seeking Alpha]
3/30
04:48 pm
amgn
Bristol Myers Squibb adding 3 medications on TrumpRx [FOX Business Network]
Low
Report
Bristol Myers Squibb adding 3 medications on TrumpRx [FOX Business Network]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/7
04:23 pm
amgn
Form DEF 14A AMGEN INC For: May 19
Medium
Report
Form DEF 14A AMGEN INC For: May 19
3/26
03:43 pm
amgn
Form SCHEDULE 13G/A AMGEN INC Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A AMGEN INC Filed by: VANGUARD GROUP INC
3/18
08:40 pm
amgn
Form 4 AMGEN INC For: Mar 16 Filed by: Santos Esteban
Low
Report
Form 4 AMGEN INC For: Mar 16 Filed by: Santos Esteban
3/18
08:39 pm
amgn
Form 4 AMGEN INC For: Mar 16 Filed by: REESE DAVID M
Low
Report
Form 4 AMGEN INC For: Mar 16 Filed by: REESE DAVID M
3/18
08:38 pm
amgn
Form 4 AMGEN INC For: Mar 16 Filed by: Miller Derek
Low
Report
Form 4 AMGEN INC For: Mar 16 Filed by: Miller Derek
3/18
08:36 pm
amgn
Form 4 AMGEN INC For: Mar 16 Filed by: Khosla Rachna
Low
Report
Form 4 AMGEN INC For: Mar 16 Filed by: Khosla Rachna
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/23
Amgen And The Amgen Foundation Commit Up To $12.5 Million To Support COVID-19 Relief Efforts
8.8%
8/8 Form 4 AMGEN INC For: Aug 07 Filed by: SUGAR RONALD D 6.2%
7/30 Amgen Reports Second Quarter 2019 Financial Results 6.1%
4/2 Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19 6.0%
8/26 UPDATE 2-Amgen to buy Celgene's psoriasis drug Otezla for $13.4 bln in cash [Reuters (UK)] 5.9%
4/7 Biotech Giant Amgen Entered The Coronavirus Arena — But Is It A Buy? [Investor's Business Daily] 5.9%
3/28 Amgen Announces Positive Results At ACC.20/WCC From Phase 3B Study Of Repatha® (Evolocumab) In People Living With HIV Who Have High LDL-Cholesterol 5.2%
8/12 Amgen, Inc. (NASDAQ: AMGN) had its "positive" rating re-affirmed by analysts at Wells Fargo & Co. They now have a $202.00 price target on the stock, up previously from $197.00. 5.0%
3/13 Amgen, Inc. (NASDAQ: AMGN) was upgraded by analysts at Cfra from a "hold" rating to a "buy" rating. 4.1%
3/26 Amgen, Inc. (NASDAQ: AMGN) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $250.00 to $240.00. They now have an "outperform" rating on the stock. 3.1%
8/8 Form 4 AMGEN INC For: Aug 07 Filed by: SUGAR RONALD D 6.2%
7/30 Amgen Reports Second Quarter 2019 Financial Results 6.1%
4/2 Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19 6.0%
8/26 UPDATE 2-Amgen to buy Celgene's psoriasis drug Otezla for $13.4 bln in cash [Reuters (UK)] 5.9%
4/7 Biotech Giant Amgen Entered The Coronavirus Arena — But Is It A Buy? [Investor's Business Daily] 5.9%
3/28 Amgen Announces Positive Results At ACC.20/WCC From Phase 3B Study Of Repatha® (Evolocumab) In People Living With HIV Who Have High LDL-Cholesterol 5.2%
8/12 Amgen, Inc. (NASDAQ: AMGN) had its "positive" rating re-affirmed by analysts at Wells Fargo & Co. They now have a $202.00 price target on the stock, up previously from $197.00. 5.0%
3/13 Amgen, Inc. (NASDAQ: AMGN) was upgraded by analysts at Cfra from a "hold" rating to a "buy" rating. 4.1%
3/26 Amgen, Inc. (NASDAQ: AMGN) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $250.00 to $240.00. They now have an "outperform" rating on the stock. 3.1%
TOP News Decliners
3/14
Amgen, Inc. (NASDAQ: AMGN) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating.
-6.8%
3/7 Hedge Funds Have Never Been This Bullish On NVIDIA Corporation (NVDA) [Yahoo! Finance News] -5.8%
2/27 Amgen, Inc. (NASDAQ: AMGN) is now covered by analysts at Barclays PLC. They set an "equal weight" rating on the stock. -5.1%
3/24 Form 4 AMGEN INC For: Mar 20 Filed by: REESE DAVID M -4.6%
4/30 Form 8-K AMGEN INC For: Apr 30 -4.6%
1/30 Q4/2019 12/31/2019 EPS 3.640 ZacksConsensus 3.470 ActVsEst 0.170 - Beat -4.5%
2/25 Amgen Stock Is Forming A Flat Base — Is It Time To Bet On AMGN Stock? [Investor's Business Daily] -3.8%
8/2 Form 4 AMGEN INC For: Aug 01 Filed by: Santos Esteban -3.1%
3/10 Form 4 AMGEN INC For: Mar 09 Filed by: REESE DAVID M -2.8%
3/31 Form 8-K AMGEN INC For: Mar 31 -2.8%
3/7 Hedge Funds Have Never Been This Bullish On NVIDIA Corporation (NVDA) [Yahoo! Finance News] -5.8%
2/27 Amgen, Inc. (NASDAQ: AMGN) is now covered by analysts at Barclays PLC. They set an "equal weight" rating on the stock. -5.1%
3/24 Form 4 AMGEN INC For: Mar 20 Filed by: REESE DAVID M -4.6%
4/30 Form 8-K AMGEN INC For: Apr 30 -4.6%
1/30 Q4/2019 12/31/2019 EPS 3.640 ZacksConsensus 3.470 ActVsEst 0.170 - Beat -4.5%
2/25 Amgen Stock Is Forming A Flat Base — Is It Time To Bet On AMGN Stock? [Investor's Business Daily] -3.8%
8/2 Form 4 AMGEN INC For: Aug 01 Filed by: Santos Esteban -3.1%
3/10 Form 4 AMGEN INC For: Mar 09 Filed by: REESE DAVID M -2.8%
3/31 Form 8-K AMGEN INC For: Mar 31 -2.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: